The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury

Journal of Clinical Investigation

Volumn 124, Issue 8, 2014, Pages 3540-3550

  Qi, Dake ^a,b   Atsina, Kwame ^a,b   Qu, Lintao ^c   Hu, Xiaoyue ^a,b   Wu, Xiaohong ^a,b   Xu, Bin ^a,b   Piecychna, Marta ^b   Leng, Lin ^b   Fingerle Rowson, Günter ^d   Zhang, Jiasheng ^a,b   Bucala, Richard ^b   Young, Lawrence H ^a,b  

^a Section of Cardiovascular Medicine   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Anesthesia ^*  (United States)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOPACHROME TAUTOMERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; DOPACHROME ISOMERASE; ISOMERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ENZYME ACTIVATION; ENZYME RELEASE; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART MUSCLE REPERFUSION; HEART SIZE; ISOLATED HEART; MALE; METABOLIC STRESS; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; REPERFUSION INJURY; 129 MOUSE; ANIMAL; BAGG ALBINO MOUSE; CELL HYPOXIA; DEFICIENCY; ENZYMOLOGY; GENETICS; HEART MUSCLE CELL; KNOCKOUT MOUSE; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PHYSIOLOGY; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE; CELL HYPOXIA; FEMALE; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED BALB C; MICE, KNOCKOUT; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84905472350     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI73061     Document Type: Article

References (50)

1. Zaha VG, Young LH. AMP-activated protein kinase regulation and biological actions in the heart. Circ Res. 2012;111(6):800-814.
2. Russell RR, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest. 2004;114(4):495-503.
3. Russell RR, Russell RR 3rd, Bergeron R, Shulman GI, Young LH. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol. 1999;277(2 pt 2):H643-H649.
4. Marsin AS, Bouzin C, Bertrand L, Hue L. The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase. J Biol Chem. 2002;277(34):30778-30783.
5. Horman S, et al. Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol. 2002;12(16):1419-1423.
6. Muoio DM, Seefeld K, Witters LA, Coleman RA. AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem J. 1999;338(pt 3):783-791.
7. Matsui Y, et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res. 2007;100(6):914-922.
8. Wang Y, et al. AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin. Circulation. 2009;119(6):835-844.
9. Paiva MA, et al. Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury. Am J Physiol Heart Circ Physiol. 2011;300(6):H2123-H2134.
10. Carvajal K, et al. Dual cardiac contractile effects of the alpha2-AMPK deletion in low-flow ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2007;292(6):H3136-H3147.
11. Minokoshi Y, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002;415(6869):339-343.
12. Yamauchi T, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288-1295.
13. Tao L, et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation. 2007;115(11):1408-1416.
14. Oshima Y, Ouchi N, Sato K, Izumiya Y, Pimentel DR, Walsh K. Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation. 2008;117(24):3099-3108.
15. Miller EJ, et al. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature. 2008;451(7178):578-582.
16. Merk M, Mitchell RA, Endres S, Bucala R. D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. Cytokine. 2012;59(1):10-17.
17. Gao XM, et al. Deletion of macrophage migration inhibitory factor protects the heart from severe ischemia-reperfusion injury: a predominant role of anti-inflammation. J Mol Cell Cardiol. 2011;50(6):991-999.
18. Qi D, et al. Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. J Clin Invest. 2009;119(12):3807-3816.
19. Garner LB, et al. Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. Am J Physiol Heart Circ Physiol. 2003;285(6):H2500-H2509.
20. Odh G, Hindemith A, Rosengren AM, Rosengren E, Rorsman H. Isolation of a new tautomerase monitored by the conversion of D-dopachrome to 5, 6-dihydroxyindole. Biochem Biophys Res Commun. 1993;197(2):619-624.
21. Sugimoto H, Taniguchi M, Nakagawa A, Tanaka I, Suzuki M, Nishihira J. Crystal structure of human D-dopachrome tautomerase, a homologue of macrophage migration inhibitory factor, at 1.54 A resolution. Biochemistry. 1999;38(11):3268-3279.
22. Merk M, et al. The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). Proc Natl Acad Sci U S A. 2011;108(34):E577-E585.
23. +/calmodulin-dependent protein kinase kinase-beta acts upstream of AMPactivated protein kinase in mammalian cells. Cell Metab. 2005;2(1):21-33.
24. Hawley SA, et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2005;2(1):9-19.
25. Tokumitsu H, Inuzuka H, Ishikawa Y, Ikeda M, Saji I, Kobayashi R. STO-609, a specific inhibitor of the Ca (2+)/calmodulin-dependent protein kinase kinase. J Biol Chem. 2002;277(18):15813-15818.
26. Bain J, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408(3):297-315.
27. Anderson KA, et al. Hypothalamic CaMKK2 contributes to the regulation of energy balance. Cell Metab. 2008;7(5):377-388.
28. Chagnon F, Metz CN, Bucala R, Lesur O. Endotoxininduced myocardial dysfunction: effects of macrophage migration inhibitory factor neutralization. Circ Res. 2005;96(10):1095-1102.
29. Gore Y, et al. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem. 2008;283(5):2784-2792.
30. Weber C, et al. Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc Natl Acad Sci U S A. 2008;105(42):16278-16283.
31. Tarzami ST, et al. Opposing effects mediated by the chemokine receptor CXCR2 on myocardial ischemia-reperfusion injury: recruitment of potentially damaging neutrophils and direct myocardial protection. Circulation. 2003;108(19):2387-2392.
32. Larocca TJ, et al. CXCR4 gene transfer prevents pressure overload induced heart failure. J Mol Cell Cardiol. 2012;53(2):223-232.
33. Racioppi L, Means AR. Calcium/calmodulindependent protein kinase kinase 2: roles in signaling and pathophysiology. J Biol Chem. 2012;287(38):31658- 31665.
34. Evankovich J, et al. Calcium/calmodulin-dependent protein kinase IV limits organ damage in hepatic ischemia-reperfusion injury through induction of autophagy. Am J Physiol Gastrointest Liver Physiol. 2012;303(2):G189-G198.
35. Joiner ML, et al. CaMKII determines mitochondrial stress responses in heart. Nature. 2012;491(7423):269-273.
36. Iwata T, et al. The action of D-dopachrome tautomerase as an adipokine in adipocyte lipid metabolism. PLoS One. 2012;7(3):e33402.
37. Brock SE, Rendon BE, Yaddanapudi K, Mitchell RA. Negative regulation of AMP-activated protein kinase (AMPK) activity by macrophage migration inhibitory factor (MIF) family members in non-small cell lung carcinomas. J Biol Chem. 2012;287(45):37917-37925.
38. Heinrichs D, et al. Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. Proc Natl Acad Sci U S A. 2011;108(42):17444-17449.
39. Bendrat K, et al. Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry. 1997;36(49):15356-15362.
40. Fingerle-Rowson G, et al. A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation. Mol Cell Biol. 2009;29(7):1922-1932.
41. Calvert JW, et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes. 2008;57(3):696-705.
42. Zhang HX, et al. Physiologically tolerable insulin reduces myocardial injury and improves cardiac functional recovery in myocardial ischemic/reperfused dogs. J Cardiovasc Pharmacol. 2006;48(6):306-313.
43. Hafstad AD, Khalid AM, How OJ, Larsen TS, Aasum E. Glucose and insulin improve cardiac efficiency and postischemic functional recovery in perfused hearts from type 2 diabetic (db/db) mice. Am J Physiol Endocrinol Metab. 2007;292(5):E1288-E1294.
44. Selker HP, et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA. 2012;307(18):1925-1933.
45. Shi X, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity. 2006;25(4):595-606.
46. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry. 1994;33(47):14144- 14155.
47. Hedhli N, et al. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation. 2011;123(20):2254-2262.
48. Li J, et al. Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart. Proc Natl Acad Sci U S A. 2013;110(40):16133-16138.
49. An D, et al. Metformin influences cardiomyocyte cell death by pathways that are dependent and independent of caspase-3. Diabetologia. 2006;49(9):2174-2184.
50. Qu L, Li Y, Pan X, Zhang P, LaMotte RH, Ma C. Transient receptor potential canonical 3 (TRPC3) is required for IgG immune complex-induced excitation of the rat dorsal root ganglion neurons. J Neurosci. 2012;32(28):9554-9562.